



सत्यमेव जयते



क.रा.बी.नि.
ESIC

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

DG-ESIC CENTRAL RATE CONTRACT NO. – 167
FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 11th DECEMBER, 2025 to 10th DECEMBER, 2027)

ANTI CANCER AND IMMUNOSUPPRESANT DRUGS

VACCINES

IMMUNOGLOBULIN

STRICTLY FOR OFFICIAL USE

मुख्यालय/HEADQUARTERS'

कमरा नंबर 312 और 321, तीसरी मंजिल, पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002

Room No. 312 & 321, 3rd Floor, Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002

www.esic.gov.in, ☎ 011-23604773, ✉ dmc-rc@esic.gov.in



क.स.बी.नि.
E S I C

S.No.	Contents	Page No.
1.	Forwarding letter along with terms & conditions for operation of Rate Contract No. 167	1-12
2.	List of Approved Pharmaceutical firms of Rate Contract No. 167	13-15
3.	Indexing of approved Items	16-20
4.	Rate Schedule of Rate Contract No. 167	21-32

क.स.बी.नि.
E S I C



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 www.esic.gov.in,
☎011-23604773, ✉ dmc-rc@esic.gov.in

No. U-25/12/165 to 169/2024-Medical.V (E-754406)/167 (RC-167)

Dated: 12.12.2025

From:

The Director General,
E.S.I. Corporation,
Panchdeep Bhawan,
C.I.G Road,
NEW DELHI - 110 002.

To

Director (Medical) Delhi/Noida
Dean-PGIMSR's/ All ESIC Medical Colleges & Hospitals/Dental Colleges
Medical Superintendent – All ESIC & ESIS Hospitals,
Director, ESI Scheme – All States & UTs.

Sub: **PROCUREMENT OF DRUGS UNDER ESIC CENTRAL RATE CONTRACT NO. 167 EFFECTIVE FROM 11.12.2025 TO 10.12.2027.**

Sir / Madam,

Please find enclosed a copy of the DG-ESIC Centralized Rate Contract duly adhering to Public Procurement (Preference to Make in India) Order, 2017 (as amended and revised till date) and related notifications from the relevant Nodal Ministry/ Department, finalized for supply of Drugs under the ESI Scheme in the country.

Validity of this Rate Contract is for a period of two years i.e. w.e.f. 11.12.2025 TO 10.12.2027.

Further, the following terms & conditions are issued to govern operation of the Rate Contract:

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers- Medical Superintendent/Dean/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his/her behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

2. Supply orders will be placed by Medical Superintendents/Deans/Director, Insurance Medical Services of various States, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and / or wherever specifically provided in the terms & conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract.
3. All the supply orders shall be signed only by the officers who have been duly authorized and included in the list of DDOs. **DDOs will send scanned copy of the Purchase Order mandatorily through email followed by speed post directly to the Approved Pharmaceutical Firm. The due date of delivery will be counted from the date of issuance of purchase order via email. It shall be the responsibility of DDOs to monitor the activity of placing purchase order via email/online module.**
4. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them.
5. The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report along with the comments and details as under: -

PROFORMA FOR NON-SUPPLY REPORT

R.C. No.	Item No. & Name of Drug	Name of firm	S.O. No. with Date	Preference (L1/L2/L3)	Qty. not supplied	Risk Purchase/ penalty levied	Payment if pending	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.

6. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.
7. It will be ensured before placing order by the Direct Demanding Officer that necessary funds are available and **payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.**
8. Supply orders/Purchase order(s) will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.



9. No guarantee can be given as to the minimum quantity which will be drawn against this contract but the approved Pharmaceutical firm will supply quantity as may be ordered by the Direct Demanding Officers during the currency of the contract.
10. The approved Pharmaceutical firm will supply the items immediately on demand or latest within six weeks of placing of supply order throughout the period of contract.
11. Supply orders/Purchase orders against the contract will be accepted as long as these reach the approved Pharmaceutical firm on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.
12. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm to supply the item as per the specifications of the relevant rate contract.

SUPPLIES

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.
14. During transit approved Pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.
15. The prices approved are F.O.R. Destination per unit and are exclusive of GST except where indicated but inclusive of all charges for packing and forwarding.
16. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.
17. **The approved Pharmaceutical firm will have to supply drugs directly in the quantity ordered, to ESIC or ESIS Institutions. The approved Pharmaceutical firm shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons. In case, at any stage of the contract, it is found that the approved Pharmaceutical firm has appointed the distributors/dealers/third party agent for making supply or receiving of supply order against the contract, ESI Corporation will initiate the following actions against the approved Pharmaceutical firm(s):**



- a. 100% forfeiture of Performance Security from the valid current all DG-ESIC Rate Contract(s).
- b. Blacklisting for participation in the future tender enquiries for all ESI Institutions for a period of two years prospectively.

18. Marking/Labelling:

Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

19. Packing:

- a) It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted/rubber stamping with indelible ink clearly. Any consignment without such stamping will not be considered valid and will be rejected.
- b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.
- c) Supplies to be made in proper boxes.
- d) Liquid orals to be supplied only in glass/ plastic bottles conforming to Drugs & Cosmetics Act and rules made there under.
- e) Large volume parenterals to be supplied only in plastic bottles / polypacks conforming to Drugs & Cosmetics Act and rules made there under.
- f) It should be ensured that only **first use packaging material of uniform size including Bottles and vials** should be used for making supplies on the basis of ESI Rate Contract.
- g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.
- h) Packing should be able to prevent damage or deterioration during transit.
- i) All containers i.e. bottle, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written on any labels otherwise it will be disqualified.
- j) All DGESIC approved pharmaceutical firm will make supply bearing Quick response code on its label at each level packaging that store data or information readable with software application to facilitate tracking and tracing as per Gazette Notification and CDSCO guidelines time to time (Where ever Applicable).



20. **Life Period :**

I:

- a) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
- b) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
- c) Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of valid shelf life from the date of manufacture.

II.

Notwithstanding the above, DDOs/Authorized nominated officer by DDO may relax this criteria in case of exigencies with reasons duly recorded and shall be responsible for use of that stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any financial loss to the Corporation.

21. **Pharmacopoeia Specifications:**

Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation supplied as per the provisions of Drug and Cosmetics Act.

22. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

23. It should be ensured that ISI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has ISI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards (Where ever Applicable).

24. **Testing of Drugs – Quality Control**

- a. Approved Rate Contract Holder should mandatorily submit a Test Report for that particular batch of medicines tested by the Government/Government approved Laboratories along with each supply, failing which supply received will be liable for rejection at the inspection stage and penalty of late supply will be levied as per provisions.
- b. Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.



- c. Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the approved Pharmaceutical firm/ firms at regular interval to maintain and ensure the quality of drugs.
- d. Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.
- e. The report of the Govt./Govt. approved laboratory shall be accepted by the approved Pharmaceutical firm. In case the same is disputed by the approved Pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However, the same should be submitted **within three months**, from the date of communication of the disputed test report to the approved Pharmaceutical firm. For this, the approved Pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory **at their own cost**. In case no response is received from the approved Pharmaceutical firm within the stipulated period, action as deemed fit as per terms & conditions of the Rate Contract will be initiated.
- f. For imported items: - The approved Pharmaceutical firm must submit the In-house test report of Principal manufacturer with each and every batch of supply.
- g. If any drug/s supplied against this Rate Contract are found to be "Not of Standard Quality" on inspection by Competent Authority, the approved Pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the approved Pharmaceutical firm/s.
- h. If the product is found to be "Not of Standard Quality", the cost of testing will be recovered from the approved Pharmaceutical firms and further action will be taken as per clause no. 25 mentioned below:
25. The classification of defects into different categories is as per the guidelines issued by the Drugs Controller General (India), Central Drugs Standard Control Organization (CDSCO) & action will be taken by ESIC for each category of defects, described as below: -
- A. CATEGORY 'A' DEFECT (Spurious / Adulterated Drugs)-**
- If any item / Batch of the item declared Not of Standard quality (NSQ) under Category A .**
- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Recoveries to be initiated by the DDO's wherever payment had been made already.
 - **100% Forfeiture of Performance Security** from the respective DGEISIC Rate Contract for all the quoted drugs.



- Debarring of the Rate Contract holder /approved Pharmaceutical firm from current and all future DGESIC Rate Contract for participation in tender enquiry of all ESIC institutions prospectively for a period of two years.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs):

1. If single item/ Batch of item is declared NSQ under Category B:

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **20% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for that drug as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item.
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

a) If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category B

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **50% (20% + 30%) Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- **Any subsequent (3rd onwards) NSQ reported** of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current and all future DGESIC Rate Contracts for a period of two years for participation in all ESI Institutions prospectively along with forfeiture of **100% performance security for all NSQ declared items.**



- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
- b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category B within a year**
 - Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
 - **100% Forfeiture of Performance Security from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.**
 - Debarring of Rate Contract Holder/approved Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for the item for a period of two years for participation in all ESI Institution prospectively.
 - Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

C. CATEGORY ' C ' DEFECT (Minor Defects)

1.If single item/ Batch of item is declared NSQ under Category C

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

2.

a)If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category-C.

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Warning to be issued to the firm for the NSQ item.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category C within a year.



- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **10% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2nd NSQ) as per clause 13(III) of TE.
- **Any subsequent (2nd NSQ onwards)** NSQ reported of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current DGESIC Rate Contracts.
- Warning to be issued to the firm for the NSQ item
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

26. **Delivery Period – Risk Purchase**

- a. Delivery period will be of six weeks from the date of **issuance of purchase order via email** and the approved Pharmaceutical firm shall execute the order within stipulated time.
- b. If the approved Pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) percent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. An approved Pharmaceutical firm can seek extension of the delivery period with the prior consent of the Direct Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. The extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned DDO.
- c. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other approved Pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate or from local chemist. All DDOs of ESIC & ESIS Institutions shall record each instance of Non-Supply of respective approved Pharmaceutical Firm and a consolidated quarterly non-supply report to be submitted at ESIC HQRS.

Extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.

- d. i) If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of approved Pharmaceutical firm. **The**

extra expenditure involved in procuring supplies from elsewhere i.e. L2 firm/other running Govt. Contract/ Local Purchase etc. will be recoverable from the approved Non-supplying Pharmaceutical firm, in full by Direct Demanding Officers.

ii) The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with bidder by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the bidder's Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than two years.

- e. If the approved Pharmaceutical firm fails to execute the supply order three times at any location of ESIC & ESIS in any part of the country during the period of rate contract, it shall be debarred for the next two years with effect from the last failure and forfeiting of Performance Security for that drug.

27. Payment

Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm/bidder to supply the items as per the specifications of the relevant rate contract. No claim for the payment from contractor shall be entertained after the lapse of three years of arising of the claim.

28. Any dues or payments that have arisen to the Corporation from the approved Pharmaceutical firm for which no specific time limit has been laid down in the terms and conditions shall be payable by the approved Pharmaceutical firm within such time limit as may be prescribed in the letters/orders addressed to the approved Pharmaceutical firms.
29. Any payments that have been demanded as per the provisions of above-mentioned clause or under any other clause shall be payable within the time laid down. On failure to do so:
- The approved Pharmaceutical firm shall be liable to be debarred for supplying items/ drugs etc. to the Corporation for a period not exceeding two years.
 - The Corporation reserves its right to take appropriate legal action against the defaulting firms as may be legally advised, including claim for compensation and damages for the period of delay and / or simple interest 10% per annum for each day of default.
30. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed: -



(a) Items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.

(b) In case of items, where two approved Pharmaceutical Firms exist at L-1(1st Preference), it is mandatory for all Direct Demanding Officers (DDOs) to place Supply Orders in the ratio of 50% of the order quantity to each L-1 approved Pharmaceutical firm on each instance of placing of supply order. Same principal applies to L2 Firm(in case order is required to be placed with L2).

(c) For item No. **2224** in **RC-167**, L-2 firms are Class-I Local Suppliers & have agreed to match the price of L-1 bidder. Therefore 50% of the order quantity to each L-1 approved Pharmaceutical firm to be placed on each instance of placing of supply order.

(d) For item No. **1735 & 2165** in **RC-167**, L-2 firms are MSE Suppliers & have agreed to match the price of L-1 bidder. Therefore 25% of the order quantity to be placed with MSE Supplier on each instance of placing of supply order.

31. No other document should be entertained for giving any cognizance for placing the supply orders.

32. The validity of the contract of approved Pharmaceutical firm holding Patent right of approved drug/s in the currency of Rate Contract shall be for two years or till date of expiry of patent whichever is earlier. It is the sole responsibility of the patent holding firm to mandatorily inform ESIC Ten days before the expiry of the Patent of the approved drug/s in Rate Contract, failing which the participating firm shall be blacklisted in the participating and prospective RCs for a period of two years along with forfeiture of EMD/ Performance security (as the case may be) as per Terms & Conditions of the Tender Enquiries.

33. The Letter of Award issued to the firms by this office cannot be used for placing orders.

34. Standing Committee on Government e-Market (SCoGeM), Ministry of Labour & Employment has granted exemption to publish and operate DG-ESIC Rate Contract for the Drugs other than drugs reserved for CPSUs.

35. Force Majeure:

If at any time during the applicability of Contract the bidder fails to discharge its Obligation due to force majeure (natural disaster or act of God etc.) he will promptly notify the Director General or its representative about the happening of such an event.

The Director General or its representative is solely entitled to terminate/ determine the order/contract in respect of such performance of the bidder(s) obligations if he so


desires. The obligations under the contract on behalf of bidder for the contract shall be resumed as soon as practicable after the event has come to an end or ceased to exist.

36. It shall be the sole responsibility of Medical Superintendents/Deans/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO/ Head of Institutions of respective State to maintain an optimum Inventory level with strict control as per ABC-VED matrix and ensure the drug formulary of the respective institution is followed in right earnest to provide medical services to ESI Beneficiaries.
37. All Deans/MSs/DIMS/Head of ESIC & ESIS Institutions are requested to keep a vigilant check on procurement of drugs (strictly monitor Re-Order Level, Buffer Stock, Lead Time etc.) in order to avoid obsolescence/expiry/excessive procurement of drugs resulting in infructuous expenditure.

This issue with the approval of Competent Authority.

Yours faithfully,

Encl.: As above.


(Dr. Sanjiv Kochhar)
Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL

Copy to:

1. PPS/PS to Director General, ESIC for information.
2. PPS/PS to Finance Commissioner for information.
3. PPS/PS to Medical Commissioner (Procurement/ Medical Administration) for information.
4. Accounts Branch – V (Hqrs. Office)
5. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.
6. Website Content Manager for uploading on ESIC HQRS Website.
7. Guard File.

डॉ. संजीव कोचर / Dr. Sanjiv Kochhar
उप विद्वान् आयुक्त / Deputy Medical Commissioner
क.रा.बी.नि.(सु.) / E.S.I.C. (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02
Panchdeep Bhawan, C.I.G. Road, New Delhi-02


(Dr. Sanjiv Kochhar)
Dy. Medical Commissioner (RC)
For: DIRECTOR GENERAL

डॉ. संजीव कोचर / Dr. Sanjiv Kochhar
उप विद्वान् आयुक्त / Deputy Medical Commissioner
क.रा.बी.नि.(सु.) / E.S.I.C. (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02
Panchdeep Bhawan, C.I.G. Road, New Delhi-02



List of Approved Pharmaceutical firms of Rate Contract No. 167

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
1.	167	BDR Pharmaceuticals International Private Limited	Registered office at : 407/408, Sharda Chambers, 15 New Marine Lines, Mumbai 400020 (Maharashtra) Admn. : Engineering Centre, 6th Floor, 9 Matthew Road, Opera House, Charni Road. Mumbai - 400004	022-40560560, 022-40560555, +91-9811383631; +91- 9136003333, manoj.kapoor@bdrpharma.com,t ender@bdrpharma.com
2.	167	Bristol Myers Squibb India Private Limited	One International Centre, 6th Floor, Tower 1, Senapati Bapat Marg, Elphinstone (W), Mumbai - 400013.	022 6628 8600, 022 6628 8700, 9820396156, tenders.india@bms.com,karan.sh arma@bms.com
3.	167	CONCORD BIOTECH LIMITED	1601-1602 B Wing, Mondeal Heights, Isckon Cross Road, S G Highway, Ahmedabad 380015 Gujarat	7968138700, 7968138725, 9830486374, tenderbusiness@concordbiotech. com,baijuvarghese@concordbiote ch.com
4.	167	Dr. Reddy's Laboratories Limited	7-1-27, Ameerpet, Hyderabad-500016, Telangana, India.	040-49048400, 040-49048800, 91 9000995868 & 91 9154302501 , ibtpricing@drreddys.com,ibt@dr reddys.com
5.	167	Eli Lilly and Company (India) Pvt. Ltd	Plot No. 92, Sector 32, Gurgaon - 122001, Haryana	0124 - 4753000, 0124 - 4753012, 9910897355, singh_inderpal@lilly.com,tendersi nfo@lilly.com
6.	167	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Limited, Glenmark House, B.D.Sawant Marg, Chakala, Andheri East, Mumbai - 400099	022-40189999, 022-40189986, 9867027126, govt.tenders@glenmarkpharma.c om
7.	167	Intas Pharmaceuticals Ltd.	Intas Pharmaceuticals Limited, Corporate House, Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad- 380054	079-39837000, 9810824433, abhishek_bajaj@intaspharma.co m
8.	167	MASCOT HEALTH SERIES PVT LTD	B-1/635, 2nd Floor, Near Janakpuri East Metro Station, Janakpuri, New Delhi 110058	011-28542407/08/10, 8800220714, gmsales.mkt@mascothealth.com, rkc.mascothealth@gmail.com



वि.प्र.अ.वि.
E S I C

List of Approved Pharmaceutical firms of Rate Contract No. 167

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
9.	167	Merck Specialities Private Limited	Godrej One, 8th Floor, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai - 400079	022 62109000, 022 62109999, 9899689294, nitesh.sharma@merckgroup.com, trendpro@merckgroup.com
10.	167	MSD PHARMACEUTICALS PRIVATE LIMITED	229, 2nd Floor, Trade Centre Premises Co Op Society Ltd. Bandra Kurla Complex, Bandra East, Mumbai - 400051.	02267898888, 02267898889, 09311866347, INDPUB@MERCK.COM,pradeep.s hetty1@merck.com
11.	167	Naprod Life Sciences Pvt. Ltd.	304, Town Center, Andheri Kurla Road, Andheri East, Mumbai- 400059	022 4093 9000, +91 8100644440, abhijit.mukherjee@naprodgroup.com,institution@naprodgroup.com
12.	167	NATCO Pharma Ltd	NATCO House, Road No. 2, Banjara Hills, Hyderabad-500034	040 23547532, 040 23548243, 8121161657, institutional@natcopharma.co.in
13.	167	Pfizer Products India Private Limited	The Capital 1802/1901, Plot No C-70, G-Block, Bandra Kurla Complex, Bandra (E) Mumbai 400051	02266932000, 02226540274, 9771414156, governmenttendersppi@pfizer.com,Satendra.seth@pfizer.com,Rajesh.kadian2@pfizer.com,vijay.pangle@pfizer.com
14.	167	Reliance Life Sciences Pvt. Ltd.	R-282 , TTC Area of MIDC, Thane Belapur Road, Navi Mumbai-400701	,+91-22-35338000, ,+91-2235338099, 8591404088, mahesh.kumar@relbio.com
15.	167	RIVPRA FORMULATION PVT. LTD,	RIVPRA FORMULATION PVT. LTD. CORPORATE OFFICE: RADISSON BLU, KM TRADE TOWER, 11TH FLOOR, OFFICE NO: 1008, H-3, KAUSHAMBI, GHAZIABAD-201010 (U.P)	(0120-4277177), 0120-4277177, 9999811834, 8800394441, tender@rivpraformulation.com,info@rivpraformulation.com
16.	167	Roche Products (India) Pvt. Ltd	Roche Products (India) Pvt Ltd, 146-B, 166 A, Unit No. 7, 8, 9,8th Floor, R City Office, R City Mall Lal Bahadur Shastri Marg,Ghatkopar, Mumbai - 400 086	91 22 50457300, 91 22 50457301, 91 9967536395, india.institutionalbusiness@roche.com,prerana.yadav@roche.com



List of Approved Pharmaceutical firms of Rate Contract No. 167

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Address of Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)
17.	167	SANOFI HEALTHCARE INDIA PRIVATE LIMITED	Sanofi house, CTS 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai - 400072. Maharashtra.	022 28032000, 022 28032939, 91 9312403063, institutionbusiness.shipl@sanofi.com, sangita.salunke@sanofi.com
18.	167	Therdose Pharma Pvt Ltd	Therdose Pharma Pvt Ltd, Road No-6, Aleap Ie, Plot no's 118-120, Pragathinagar-Hyderabad-90	80008695151, 040-6565455, 9154971773, tenders@therdose.com, arvind.p@therdose.com
19.	167	Virchow Biotech Pvt. Ltd.	Virchow Biotech Pvt. Ltd., 901, Dlh Park, S V Road, Goregaon West, Mumbai, Mumbai Suburban, Maharashtra, 400062	022-28795635/022-28735609, 022-28795699, 9833197751, shambhu.s@virchowpharma.com, kiran.saxena@virchowpharma.com
20.	167	Zydus Lifesciences Limited	Zydus Lifesciences Limited 4th Floor, "B" Wing, 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S.G.Highway, Ahmedabad - 382 481, Gujarat, India.	+91-079-71800000, 91-079-48040000, +91-079-71800192, +91-91-98723 14125, ZLL_Institution_Business@zyduslife.com, NishuS.Dubey@zyduslife.com

क.स.बी.नि.
ESIC

भारत सरकार
ESIC**Index RC- 167**

S.No.	RC No.	Item No.	Item Name and Description
1	167	290	Etoposide Inj- Each Vial to contain: Etoposide IP 100mg
2	167	458	Fludarabine Inj- Each Vial to contain: Fludarabine 50mg.
3	167	504	Imatinib Tab/Cap- Each Tab/Cap to contain: Imatinib Mesylate 100mg
4	167	1336	Cyclosporin Syp - Each ml to contain: Cyclosporin 100 mg.
5	167	1406	Temozolomide Tab/ Cap- Each Tab/Cap to contain: Temozolomide IP 250mg
6	167	1453	Letrolzole 2.5mg Tab
7	167	1465	Paclitaxel Inj- Each vial to contain: Paclitaxel 300mg
8	167	1640	Lapatinib Tab/Cap-Each Tab/Cap to contain: Lapatinib 250mg
9	167	1641	Aprepitant Tab/Cap- Each Pack to contain: Aprepitant (125 mg One Tab/Cap and 80 mg Two Tab/Cap)
10	167	1645	Paclitaxel Inj-Each Vial to contain: Inj Paclitaxel IP 30mg
11	167	1728	Gefitinib Tab/Cap- Each Tab/Cap to contain: Gefitinib 250mg.
12	167	1732	Decitabine Inj-Each Vial to contain: Decitabine 50mg
13	167	1733	Nilotinib Tab/Cap-Each Tab/Cap to contain: Nilotinib 150mg
14	167	1735	Imatinib Tab/Cap-Each Tab/Cap to contain: Imatinib Mesylate Equivalent to Imatinib 400 mg
15	167	1807	Erlotinib 100mg Tab/Cap - Each Tab/Cap to contain: Erlotinib Hydrochloride equivalent to Erlotinib 100mg
16	167	1808	Bortezomib Inj- Each Vial to contain: Bortezomib 1 mg
17	167	1810	Nilotinib 200MG Tab/Cap-Each Tab/Cap To contain: Nilotinib 200mg
18	167	1812	Cetuximab Inj (100mg)- Each ml to contain: Cetuximab 5mg,20ml Vial
19	167	1813	Cetuximab Inj (500mg)- Each ml to contain: Cetuximab 5mg,100ml Vial
20	167	1985	Temozolomide Tab/Cap- Each Tab/Cap to contain:



म.प्र.जी.सि.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
			Temozolomide 100mg
21	167	2121	Adalimumab Inj- Each Pre-Filled Syringe to contain: Adalimumab 20mg/ 0.4ml Composition Adalimumab 20mg, Succinic Acid 0.472mg, Sodium Hydroxide NF Q.S. To pH 5.2 Sodium Chloride USP 2.336mg, L-Arginine Monohydrochloride USP 2mg, Sorbitol NF 4mg, Polysorbate 80 NF 0.04mg WFI Q.S. To 0.4ml
22	167	2123	Docetaxel Lipid Suspension 80 MG Inj. (Nanosomal)
23	167	2124	Pazopanib Tab/Cap- Each Film Coated Tab/Cap to contain: Pazopanib Hydrochloride Equivalent to 400mg Pazopanib
24	167	2125	Eltrombopag Tab/Cap- Each Film Coated Tab/Cap to contain: Eltrombopag Olamine Equivalent to 25mg Of Eltrombopag as Eltrombopag Free Acid
25	167	2126	Eltrombopag Tab/Cap- Each Film Coated Tab/Cap to contain: Eltrombopag Olamine Equivalent to 50mg Of Eltrombopag as Eltrombopag Free Acid
26	167	2147	Adalimumab Inj- Each Pre-Filled Syringe to contain: Adalimumab 40mg/ 0.8ml
27	167	2155	Permetrexed Inj- Each Vial to contain: Permetrexed 100mg
28	167	2161	Fulvestrant Inj-Each Vial to contain: Fulvestrant 250mg
29	167	2165	Abiraterone Acetate Tab/Cap-Each Tab/Cap to contain: Abiraterone Acetate 250 Mg
30	167	2166	Docetaxel Lipid Suspension 20 MG Inj. (Nanosomal)
31	167	2175	Bendamustine Inj- Each Vial to contain: Bendamustine Hcl 100mg
32	167	2217	Rabbit Antithymocyte Globulin - Each 5ml to contain: Rabbit Antithymocyte Globulin 25mg
33	167	2224	Bevacizumab injection- Each Inj to contain: Bevacizumab 400 mg
34	167	2229	Human Immunoglobulin Inj- Each Bottle to contain: Human Immunoglobulin 5gm/100 ml (IVIG), 100ml Bottle



ए. ए. सी. ई.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
35	167	2322	Mitomycin Inj- Each Vial/Amp to contain: Mitomycin 2mg
36	167	2328	Calcium Polystyrene Sulfonate Sachet- Each Sachet to contain: Calcium Polystyrene Sulfonate 15 gm
37	167	2453	Dacarbazine Inj- Each Vial/Amp to contain: Dacarbazine 200mg
38	167	2454	Melphalan Hydrochloride Inj. -Each Vial/Amp to contain: Melphalan Hydrochloride 50mg
39	167	2455	Olaparib Tab/Cap-Each Tab/Cap contain: Olaparib 150mg
40	167	2459	Tolvaptan Tab/Cap- Each Tab/Cap contain: Tolvaptan 15mg
41	167	2652	Abemaciclib Tab/Cap: Each tab/cap to contain Abemaciclib 150mg
42	167	2653	Abemaciclib Tab/Cap: Each tab/cap to contain Abemaciclib 100mg
43	167	2654	Abemaciclib Tab/Cap: Each tab/cap to contain Abemaciclib 50mg
44	167	2655	Abiraterone Tab/Cap: Each tab/cap to contain Abiraterone 500 mg
45	167	2656	Abrocitinib Tab/Cap: Each tab/cap to contain Abrocitinib 50mg
46	167	2657	Abrocitinib Tab/Cap: Each tab/cap to contain Abrocitinib 100mg
47	167	2658	Abrocitinib Tab/Cap: Each tab/cap to contain Abrocitinib 200mg
48	167	2664	Cabazitaxel injection: Cabazitaxel 60mg/1.5ml
49	167	2665	Cabozantinib tab/cap: Each Tab/Cap to contain Cabozantinib 20mg.
50	167	2666	Cabozantinib tab/cap: Each Tab/Cap to contain Cabozantinib 40mg.
51	167	2667	Cabozantinib tab/cap: Each Tab/Cap to contain Cabozantinib 60mg.
52	167	2672	Docaravimab + Miromavimab Injection 600 IU: Contain Docaravimab(300 IU)and Miromavimab (300 IU)/ML
53	167	2673	Endoxifen 8 mg Tab



ए. ए. सी. ई. सी.
E S I C

S.No.	RC No.	Item No.	Item Name and Description
54	167	2675	Enzalutamide tab/cap:Each Tab/cap to contain Enzalutamide 40mg
55	167	2676	Enzalutamide tab/cap:Each Tab/cap to contain Enzalutamide 80mg
56	167	2679	Human Papillomavirus 9-valent vaccine, Recombinant [Serotypes:[Type 6 L1,11L1,16L1, 18L1,31L1,33L1,45L1,52 L1 & 58L1], 0.5ml vial/PFS
57	167	2681	Ipilimumab Injection: Each vial/amp of 10 ml contain ipilimumab 50mg Injection (5mg/ml),1 vial of 10ml.
58	167	2682	Pegylated Liposomal Doxorubicin 20 mg Hcl Vial
59	167	2683	Pegylated Liposomal Doxorubicin 50 mg Hcl Vial
60	167	2685	Pertuzumab 600mg + Trastuzumab 600mg injection(600mg + 600mg/10ml)
61	167	2686	Polatuzumab Injection:Each vial/amp to contain Polatuzumab vedotin 30mg
62	167	2688	Pomalidomide Tab/Cap:Each Tab/Cap to contain Pomalidomide 1mg
63	167	2689	Pomalidomide Tab/Cap:Each Tab/Cap to contain Pomalidomide 2mg
64	167	2690	Pomalidomide Tab/Cap:Each Tab/Cap to contain Pomalidomide 4mg
65	167	2691	Rucaparib Tab/Cap:Each Tab/Cap to contain Rucaparib 200mg
66	167	2692	Rucaparib Tab/Cap:Each Tab/Cap to contain Rucaparib 300mg
67	167	2693	Sirolimus Tab/Cap:Each Tab/Cap to contain Sirolimus 1 mg
68	167	2696	Pneumococcal Inj. -0.5ml(23 Variant),0.5ml single dose
69	167	1331b	Mitomycin Inj- Each Vial to contain: Mitomycin 10mg
70	167	1407a	Epirubicin Inj- Each Inj to contain: Epirubicin Hydrochloride 10mg
71	167	1407b	Epirubicin Inj- Each Inj to contain: Epirubicin Hydrochloride 50mg
72	167	1447a	Dasatinib Tab/Cap-Each TabCap to contain: Dasatinib 20mg
73	167	1447b	Dasatinib Tab/Cap-Each Tab/Cap to contain: Dasatinib 50mg



क.स.बी.नि.
ESIC

S.No.	RC No.	Item No.	Item Name and Description
74	167	1449a	Rituximab Inj- Each vial to contain:Rituximab 100mg
75	167	1449b	Rituximab Inj- Each vial to contain: Rituximab 500mg
76	167	1474a	Everolimus Tab/Cap-Each Tab/Captocontain:Everolimus 0.25mg
77	167	1474b	Everolimus Tab/Cap-Each Tab/Captocontain:Everolimus 0.5mg
78	167	1476a	Deferasirox Tab/Cap-Each Tab/Cap to contain Deferasirox 100mg.
79	167	1650b	Filgrastim 300 mcg Vial
80	167	459a	Gemcitabine Inj- Each Vial to contain: Gemcitabine 200mg

f

क.स.बी.नि.
ESIC

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Naprod Life Sciences Pvt. Ltd.	290	Etoposide Inj-Each Vial to contain: Etoposide IP 100mg	1 Vial	Nzytop	1 Vial	119/1 Vial	Rupees One Hundred Nineteen Only	L-1
167	Therdose Pharma Pvt. Ltd.	458	Fludarabine Inj- Each Vial to contain: Fludarabine 50mg.	1 Vial	Fludarither 50	1 Vial	1700/1 Vial	Rupees One Thousand Seven Hundred Only	L-1
167	Therdose Pharma Pvt. Ltd.	504	Imatinib Tab/Cap- Each Tab/Cap to contain: Imatinib Mesylate 100mg	1 Tab/Cap	Imated 100	10 Tab	6.10/1 Tab	Rupees Six Paise Ten Only	L-1
167	NATCO Pharma Ltd	504	Imatinib Tab/Cap- Each Tab/Cap to contain: Imatinib Mesylate 100mg	1 Tab/Cap	VEENAT 100	10 Cap	6.20/1 Cap	Rupees Six Paise Twenty Only	L-2
167	BDR Pharmaceuticals International Private Limited	504	Imatinib Tab/Cap-Each Tab/Cap to contain: Imatinib Mesylate 100mg	1 Tab/Cap	APOTINIB 100	10 Tab	6.43/1 Tab	Rupees Six Paise Forty Three Only	L-3
167	RIVPRA FORMULATION PVT. LTD.	1336	Cyclosporin Syp-Each ml to contain: Cyclosporin 100 mg.	1 ml	PORINE	50ml Bottle	37/1ml	Rupees Thirty Seven Only	L-1
167	Therdose Pharma Pvt. Ltd.	1406	Temozolomide Tab/ Cap- Each Tab/Cap to contain: Temozolomide IP 250mg	1 Tab/Cap	Temother 250	5 Cap	71.15/1 Cap	Rupees Seventy One Paise Fifteen Only	L-1
167	Intas Pharmaceuticals Ltd.	1453	Letrozole Tab/Cap-Each Tab/Cap to contain: Letrozole 2.5mg	1 Tab/Cap	LETALL	10 Tab	2.70/1 Tab	Rupees Two Paise Seventy Only	L-1
167	Naprod Life Sciences Pvt. Ltd.	1465	Paclitaxel Inj-Each vial to contain: Paclitaxel 300mg	1 Vial	Same as in Item	1 Vial	912/1 Vial	Rupees Nine Hundred Twelve Only	L-1
167	Therdose Pharma Pvt. Ltd.	1465	Paclitaxel Inj- Each vial to contain: Paclitaxel 300mg	1 Vial	Paclither 300	1 Vial	1250/1 Vial	Rupees One Thousand Two Hundred Fifty Only	L-2
167	BDR Pharmaceuticals International Private Limited	1640	Lapatinib Tab/Cap-Each Tab/Cap to contain: Lapatinib 250mg	1 Tab/Cap	LANIB 250	30 Tab	54.90/1 Tab	Rupees Fifty Four Paise Ninety Only	L-1
167	NATCO Pharma Ltd	1640	Lapatinib Tab/Cap- Each Tab/Cap to contain: Lapatinib 250mg	1 Tab/Cap	HERDUO	30 Tab	56.00/1 Tab	Rupees Fifty Six Only	L-2

E S I C

[Signature]
21 | Page

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Glenmark Pharmaceuticals Limited	1641	Aprepitant Tab/Cap-Each Pack to contain: Aprepitant (125 mg One Tab/Cap and 80 mg Two Tab/Cap)	1 Pack	APRECAP CAPSULES	1 Pack	108/1 Pack	Rupees One Hundred Eight Only	L-1
167	RIVPRA FORMULATION PVT. LTD.	1641	Aprepitant Tab/Cap-Each Pack to contain: Aprepitant (125 mg One Tab/Cap and 80 mg Two Tab/Cap)	1 Pack	Same as in Item	1 Pack	490/1 Pack	Rupees Four Hundred Ninety Only	L-2
167	Naprod Life Sciences Pvt. Ltd.	1645	Paclitaxel Inj-Each Vial to contain: Inj Paclitaxel IP 30mg	1 Vial	Same as in Item	1 Vial	104.40/1 Vial	Rupees One Hundred Four Paise Forty Only	L-1
167	Therdose Pharma Pvt. Ltd.	1645	Paclitaxel Inj-Each Vial to contain: Inj Paclitaxel IP 30mg	1 Vial	Paclither 30	1 Vial	150/1 Vial	Rupees One Hundred Fifty Only	L-2
167	Therdose Pharma Pvt. Ltd.	1728	Gefitinib Tab/Cap- Each Tab/Cap to contain: Gefitinib 250mg.	1 Tab/Cap	Zefyted 250	10 Tab	15.40/1 Tab	Rupees Fifteen Paise Forty Only	L-1
167	BDR Pharmaceuticals International Private Limited	1732	Decitabine Inj-Each Vial to contain: Decitabine 50mg	1 Vial	D-NIB 50	1 Vial	799.75/1 Vial	Rupees Seven Hundred Ninety Nine Paise Seventy Five Only	L-1
167	Therdose Pharma Pvt. Ltd.	1732	Decitabine Inj- Each Vial to contain: Decitabine 50mg	1 Vial	Decitother 50	1 Vial	1300/1 Vial	Rupees One Thousand Three Hundred Only	L-2
167	BDR Pharmaceuticals International Private Limited	1733	Nilotinib Tab/Cap-Each Tab/Cap to contain: Nilotinib 150mg	1 Tab/Cap	NILOSURE 150	4 Cap	33.00/1 Cap	Rupees Thirty Three Only	L-1
167	BDR Pharmaceuticals International Private Limited	1735	Imatinib Tab/Cap-Each Tab/Cap to contain: Imatinib Mesylate Equivalent to Imatinib 400 mg	1 Tab/Cap	APOTINIB 400	10 Tab	12.49/1 Tab	Rupees Twelve Paise Forty Nine Only	L-1 (75% of Order Quantity)
167	Therdose Pharma Pvt. Ltd.	1735	Imatinib Tab/Cap- Each Tab/Cap to contain: Imatinib Mesylate Equivalent to Imatinib 400 mg	1 Tab/Cap	Imated 400	10 Tab	12.49/1 Tab	Rupees Twelve Paise Forty Nine Only	L-1 (25% of Order Quantity, MSE Supplier)

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Therdose Pharma Pvt. Ltd.	1807	Erlotinib 100mg Tab/Cap – Each Tab/Cap to contain: Erlotinib Hydrochloride equivalent to Erlotinib 100mg	1 Tab/Cap	Erloted 100	10 Tab	29.00/1 Tab	Rupees Twenty Nine Only	L-1
167	NATCO Pharma Ltd.	1807	Erlotinib 100mg Tab/Cap – Each Tab/Cap to contain: Erlotinib Hydrochloride equivalent to Erlotinib 100mg	1 Tab/Cap	ERLONAT 100	30 Tab	36.00/1 Tab	Rupees Thirty Six Only	L-2
167	Therdose Pharma Pvt. Ltd.	1808	Bortezomib Inj- Each Vial to contain: Bortezomib 1 mg	1 Vial	Bortether 1	1 Vial	322/1 Vial	Rupees Three Hundred Twenty Two Only	L-1
167	BDR Pharmaceuticals International Private Limited	1810	Nilotinib 200MG Tab/Cap-Each Tab/Cap To contain: Nilotinib 200mg	1 Tab/Cap	NILOSURE 200	4 Cap	42.20/1 Cap	Rupees Forty Two Paise Twenty Only	L-1
167	Merck Specialities Private Limited	1812	Cetuximab Inj (100mg)- Each ml to contain: Cetuximab 5mg,20ml Vial	1 Vial/Amp	Erbitux 100mg/20ml (Mfd. by Merck Healthcare KGaA, Germany)	20ml Vial	15811.01/1 Vial	Rupees Fifteen Thousand Eight Hundred Eleven Paise One Only	L-1
167	Merck Specialities Private Limited	1813	Cetuximab Inj (500mg)- Each ml to contain: Cetuximab 5mg,100ml Vial	1 Vial/Amp	Erbitux 500mg/100ml (Mfd. by Merck Healthcare KGaA, Germany)	100ml Vial	79055.06/1 Vial	Rupees Seventy Nine Thousand Fifty Five Paise Six Only	L-1
167	Therdose Pharma Pvt Ltd	1985	Temozolomide Tab/Cap- Each Tab/Cap to contain: Temozolomide 100mg	1 Tab/Cap	Temother 100	5 Cap	57.00/1 Cap	Rupees Fifty Seven Only	L-1

क.स.बी.नि.

ESIC

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Zydus Lifesciences Limited	2121	Adalimumab Inj-Each Pre-Filled Syringe to contain: Adalimumab 20mg/ 0.4ml Composition Adalimumab 20mg, Succinic Acid 0.472mg, Sodium Hydroxide NF Q.S. To pH 5.2 Sodium Chloride USP 2.336mg, L-Arginine Monohydrochloride USP 2mg, Sorbitol NF 4mg, Polysorbate 80 NF 0.04mg WFI Q.S. To 0.4ml	1 PFS	EXEMPTIA 20	1 PFS	3444/1 PFS	Rupees Three Thousand Four Hundred Forty Four Only	L-1
167	Intas Pharmaceuticals Ltd.	2123	Docetaxel Lipid Suspension 80mg Inj. (Nanosomal)	1 Vial	DOCEAQUALIP 80 MG	Vial	9980/1 Vial	Rupees Nine Thousand Nine Hundred Eighty Only	L-1
167	Therdose Pharma Pvt Ltd	2124	Pazopanib Tab/Cap-Each Film Coated Tab/Cap to contains Pazopanib Hydrochloride Equivalent to 400mg Pazopanib	1 tab	Pazother 400	10 Tab	39.00/1 Tab	Rupees Thirty Nine Only	L-1
167	BDR Pharmaceuticals International Private Limited	2124	Pazopanib Tab/Cap-Each Film Coated Tab/Cap to contains Pazopanib Hydrochloride Equivalent to 400mg Pazopanib	1 Tab/Cap	BDPAZO 400MG	30 Tab	56.16/1 Tab	Rupees Fifty Six Paise Sixteen Only	L-2
167	Zydus Lifesciences Limited	2125	Eltrombopag Tab/Cap-Each Film Coated Tab/Cap to contain: Eltrombopag Olamine Equivalent to 25mg Of Eltrombopag as Eltrombopag Free Acid	1 Tab/Cap	ELROMO 25	7 Tab	19.00/1 Tab	Rupees Nineteen Only	L-1
167	MASCOT HEALTH SERIES PVT LTD	2125	Eltrombopag Tab/Cap-Each Film Coated Tab/Cap to contain: Eltrombopag Olamine Equivalent to 25mg Of Eltrombopag as Eltrombopag Free Acid	1 Tab/Cap	ELTROMAS-25	10 Tab	46.00/1 Tab	Rupees Forty Six Only	L-2

ESIC

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Zydus Lifesciences Limited	2126	Eltrombopag Tab/Cap-Each Film Coated Tab/Cap to contain: Eltrombopag Olamine Equivalent to 50mg Of Eltrombopag as Eltrombopag Free Acid	1 Tab/Cap	ELROMO 50	7 Tab	45.00/1 Tab	Rupees Forty Five Only	L-1
167	MASCOT HEALTH SERIES PVT LTD	2126	Eltrombopag Tab/Cap-Each Film Coated Tab/Cap to contain: Eltrombopag Olamine Equivalent to 50mg Of Eltrombopag as Eltrombopag Free Acid	1 Tab/Cap	ELTROMAS-50	10 Tab	68.00/1 Tab	Rupees Sixty Eight Only	L-2
167	Zydus Lifesciences Limited	2147	Adalimumab Inj-Each Pre-Filled Syringe to contain: Adalimumab 40mg/ 0.8ml	1 PFS	EXEMPTIA 40	1 PFS	4008/1 PFS	Rupees Four Thousand Eight Only	L-1
167	Naprod Life Sciences Pvt. Ltd.	2155	Permetrexed Inj-Each Vial to contain: Permetrexed 100mg	1 Vial	Same as in Item	1 Vial	287.00/1 Vial	Rupees Two Hundred Eighty Seven Only	L-1
167	BDR Pharmaceuticals International Private Limited	2155	Permetrexed Inj-Each Vial to contain: Permetrexed 100mg	1 Vial	PEMETREX 100	1 Vial	552/1 Vial	Rupees Five Hundred Fifty Two Only	L-2
167	BDR Pharmaceuticals International Private Limited	2161	Fulvestrant Inj-Each Vial to contain: Fulvestrant 250mg	1 PFS	V-STRANT	1 PFS	2513.70/1 PFS	Rupees Two Thousand Five Hundred Thirteen Paise Seventy Only	L-1
167	BDR Pharmaceuticals International Private Limited	2165	Abiraterone Acetate Tab/Cap-Each Tab/Cap to contain: Abiraterone Acetate 250 Mg	1 Tab/Cap	BDRON 250	120 Tab	22.95/1 Tab	Rupees Twenty Two Paise Ninety Five Only	L-1 (75% of Order Quantity)
167	Therdose Pharma Pvt Ltd	2165	Abiraterone Acetate Tab/Cap-Each Tab/Cap to contain: Abiraterone Acetate 250 Mg	1 Tab/Cap	Inveteron 250	120 Tab	22.95/1 Tab	Rupees Twenty Two Paise Ninety Five Only	L-1 (25% of Order Quantity, MSE Supplier)
167	Intas Pharmaceuticals Ltd.	2166	Docetaxel Lipid Suspension 20 MG Inj. (Nanosomal)	1 Vial	DOCEAQUALIP 20 MG (Nanosomal)	Vial	2490/1 Vial	Rupees Two Thousand Four Hundred Ninety Only	L-1

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Naprod Life Sciences Pvt. Ltd.	2175	Bendamustine Inj-Each Vial to contain: Bendamustine Hcl 100mg	1 Vial	Bendamustine for Injection IP	1 Vial	690/1 Vial	Rupees Six Hundred Ninety Only	L-1
167	Therdose Pharma Pvt Ltd	2175	Bendamustine Inj-Each Vial to contain: Bendamustine Hcl 100mg	1 Vial	Thermustine 100	1 Vial	1200/1 Vial	Rupees One Thousand Two Hundred Only	L-2
167	SANOFI HEALTHCARE INDIA PRIVATE LIMITED	2217	Rabbit Antithymocyte Globulin: Each 5ml to contain: Rabbit Antithymocyte Globulin 25mg	1 Vial	Thymoglobuline (Mfd. by M/s Genzyme Ireland Ltd, Ireland)	25mg Vial	17700/1 Vial	Rupees Seventeen Thousand Seven Hundred Only	L-1
167	Dr. Reddy's Laboratories Limited	2224	Bevacizumab injection-Each Inj to contain: Bevacizumab 400 mg	1 Vial	Versavo 400	1 Vial	4996/1 Vial	Rupees Four Thousand Nine Hundred Ninety Six Only	L-1 (50% of Order Quantity)
167	Intas Pharmaceuticals Ltd.	2224	Bevacizumab injection-Each Inj to contain: Bevacizumab 400 mg	1 Vial	BEVATAS 400	1 Vial	4996/1 Vial	Rupees Four Thousand Nine Hundred Ninety Six Only	L-1 (50% of Order Quantity, Class-I Local Supplier)
167	Reliance Life Sciences Pvt. Ltd.	2224	Bevacizumab injection-Each Inj to contain: Bevacizumab 400 mg	1 Vial	Bevacirel	1 Vial	6500/1 Vial	Rupees Six Thousand Five Hundred Only	L-3
167	Virchow Biotech Pvt. Ltd.	2229	Human Immunoglobulin Inj-Each Bottle to contain: Human Immunoglobulin 5gm/100 ml (IVIG),100ml Bottle	1ml	V-Immune	100ml Bottle	65.00/1ml	Rupees Sixty Five Only	L-1
167	Intas Pharmaceuticals Ltd.	2229	Human Immunoglobulin Inj-Each Bottle to contain: Human Immunoglobulin 5gm/100 ml (IVIG),100ml Bottle	1ml	GLOBUCEL	100ml Vial	68.88/1ml	Rupees Six Thousand Eight Hundred Eighty Eight Only	L-2
167	Naprod Life Sciences Pvt. Ltd.	2322	Mitomycin Inj-Each Vial/Amp to contain: Mitomycin 2mg	1 Vial/Amp	Vesimycin 2	1 Vial	175/1 Vial	Rupees One Hundred Seventy Five Only	L-1

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	RIVPRA FORMULATION PVT. LTD.	2328	Calcium Polystyrene Sulfonate Sachet- Each Sachet to contain: Calcium Polystyrene Sulfonate 15 gm	1 Sachet	CALCIMEN-P	1 Sachet	83.00/ 1 Sachet	Rupees Eighty Three Only	L-1
167	Zydus Lifesciences Limited	2328	Calcium Polystyrene Sulfonate Sachet- Each Sachet to contain: Calcium Polystyrene Sulfonate 15 gm	1 Sachet	K-BIND	1 Sachet	86.00/ 1 Sachet	Rupees Eighty Six Only	L-2
167	Naprod Life Sciences Pvt. Ltd.	2453	Dacarbazine Inj-Each Vial/Amp to contain: Dacarbazine 200mg	1 Vial/Amp	Arzi 200	1 Vial	207/1 Vial	Rupees Two Hundred Seven Only	L-1
167	Therdose Pharma Pvt Ltd	2454	Melphalan Hydrochloride Inj.-Each Vial/Amp to contain: Melphalan Hydrochloride 50mg	1 Vial	Melphather 50	1 Vial	800/1 Vial	Rupees Eight Hundred Only	L-1
167	BDR Pharmaceuticals International Private Limited	2455	Olaparib Tab/Cap-Each Tab/Cap contain: Olaparib 150mg	1 Tab/Cap	BDPARB 150	28 Tab	71.28/1 Tab	Rupees Seventy One Paise Twenty Eight Only	L-1
167	RIVPRA FORMULATION PVT. LTD.	2459	Tolvaptan Tab/Cap-Each Tab/Cap contain: Tolvaptan 15mg	1 Tab/Cap	Same as in Item	10 Tab	9.85/1 Tab	Rupees Nine Paise Eighty Five Only	L-1
167	Eli Lilly and Company (India) Pvt. Ltd.	2652	Abemaciclib Tab/Cap: Each tab/cap to contain Abemaciclib 150mg	1 Tab/Cap	RAMIVEN 150 MG (Mfd. by M/s Lilly S.A. Spain)	7 Tab	1096.35/ 1 Tab	Rupees One Thousand Ninety Six Paise Thirty Five Only	L-1
167	Eli Lilly and Company (India) Pvt. Ltd	2653	Abemaciclib Tab/Cap: Each tab/cap to contain Abemaciclib 100mg	1 Tab/Cap	RAMIVEN 100 MG (Mfd. by M/s Lilly S.A. Spain)	7 Tab	1096.35/ 1 Tab	Rupees One Thousand Ninety Six Paise Thirty Five Only	L-1
167	Eli Lilly and Company (India) Pvt. Ltd	2654	Abemaciclib Tab/Cap: Each tab/cap to contain Abemaciclib 50mg	1 Tab/Cap	RAMIVEN 50 MG (Mfd. by M/s Lilly S.A. Spain)	7 Tab	1096.35/ 1 Tab	Rupees One Thousand Ninety Six Paise Thirty Five Only	L-1
167	BDR Pharmaceuticals International Private Limited	2655	Abiraterone Tab/Cap: Each tab/cap to contain Abiraterone 500 mg	1 Tab/Cap	BDRON 500	60 Tab	55.62/1 Tab	Rupees Fifty Five Paise SixtyTwo Only	L-1

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Pfizer Products India Private Limited	2656	Abrocitinib Tab/Cap: Each tab/cap to contain Abrocitinib 50mg	1 Tab/Cap	CIBINQO 50mg (Mfd. by Pfizer Manufacturing deutschland GmbH, Germany)	7 Tab	1105/1 Tab	Rupees One Thousand One Hundred Five Only	L-1
167	Pfizer Products India Private Limited	2657	Abrocitinib Tab/Cap: Each tab/cap to contain Abrocitinib 100mg	1 Tab/Cap	CIBINQO 100mg (Mfd. by Pfizer Manufacturing deutschland GmbH, Germany)	7 Tab	1381/1 Tab	Rupees One Thousand Three Hundred Eighty One Only	L-1
167	Pfizer Products India Private Limited	2658	Abrocitinib Tab/Cap: Each tab/cap to contain Abrocitinib 200mg	1 Tab/Cap	CIBINQO 100mg (Mfd. by Pfizer Manufacturing deutschland GmbH, Germany)	7 Tab	1885/1 Tab	Rupees One Thousand Eight Hundred Eighty Five Only	L-1
167	BDR Pharmaceuticals International Private Limited	2664	Cabazitaxel injection: Cabazitaxel 60mg/1.5ml	1 Vial	Z-TEXEL	1 Vial	2970/1 Vial	Rupees Two Thousand Nine Hundred Seventy Only	L-1
167	BDR Pharmaceuticals International Private Limited	2665	Cabozantinib Tab/Cap: Each Tab/Cap to contain Cabozantinib 20mg.	1 Tab/Cap	CABOZANIB 20	30 Tab	27.50/1 Tab	Rupees Twenty Seven Paise Fifty Only	L-1
167	BDR Pharmaceuticals International Private Limited	2666	Cabozantinib Tab/Cap: Each Tab/Cap to contain Cabozantinib 40mg.	1 Tab/Cap	CABOZANIB 40	30 Tab	55.00/1 Tab	Rupees Fifty Five Only	L-1
167	BDR Pharmaceuticals International Private Limited	2667	Cabozantinib tab/cap: Each Tab/Cap to contain Cabozantinib 60mg.	1 Tab/Cap	CABOZANIB 60	30 Tab	82.50/1 Tab	Rupees Eighty Two Paise Fifty Only	L-1

ESIC

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Zydus Lifesciences Limited	2672	Docaravimab + Miromavimab Injection 600 IU: Contain Docaravimab(300 IU)and Miromavimab (300 IU)/ML	1 Vial/Amp/PFS	TWINRAB	1 Vial	1200/1 Vial	Rupees One Thousand Two Hundred Only	L-1
167	Intas Pharmaceuticals Ltd.	2673	Endoxifen tab/cap:Each Tab/Cap to contain Endoxifen 8mg.	1 Tab/Cap	ZONALTA	10 Tab	71.43/1 Tab	Rupees Seventy One Paise Forty Three Only	L-1
167	BDR Pharmaceuticals International Private Limited	2675	Enzalutamide Tab/Cap: Each Tab/cap to contain Enzalutamide 40mg	1 Tab/Cap	BDENZA 40	28 Cap	30.85/1 Cap	Rupees Thirty Paise Eighty Five Only	L-1
167	BDR Pharmaceuticals International Private Limited	2676	Enzalutamide Tab/Cap: Each Tab/cap to contain Enzalutamide 80mg	1 Tab/Cap	BDENZA 80	14 Cap	101.40/1 Cap	Rupees One Hundred One Paise Forty Only	L-1
167	MSD PHARMACEUTICALS PRIVATE LIMITED	2679	Human Papillomavirus 9-valent vaccine, Recombinant Serotypes: [Type 6 L1,11L1,16L1, 18L1,31L1,33L1,45L1,52 L1 & 58L1], 0.5ml vial/PFS	1 Vial/Amp/PFS	Gardasil 9 (Mfd. by: Merck Sharp & Dohme, Netherlands)	0.5 ml single dose vial and pre filled syringes	3000/1 PFS	Rupees Three Thousand Only	L-1
167	Bristol Myers Squibb India Private Limited	2681	Ipilimumab Injection: Each vial/amp of 10 ml contain ipilimumab 50mg Injection (5mg/ml),1 vial of 10ml.	1 Vial/Amp	Yervoi (Mfd. by: Bristol-Mayers Squibb, USA)	1 Vial	59524/1 Vial	Rupees Fifty Nine Thousand Five Hundred Twenty Four Only	L-1
167	Intas Pharmaceuticals Ltd.	2682	Pegylated Liposomal Doxorubicin 20 mg Hcl Vial	1ml	PEGADRIA 20	10ml Vial	649/1 Vial	Rupees Six Hundred Forty Nine Only	L-1
167	Intas Pharmaceuticals Ltd.	2683	Pegylated Liposomal Doxorubicin 50 mg Hcl Vial	1ml	PEGADRIA 50	25ml Vial	1149/1 Vial	Rupees One Thousand One Hundred Forty Nine Only	L-1

क.रा.बो.नि.
ESIC

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Roche Products (India) Pvt. Ltd	2685	Pertuzumab 600mg + Trastuzumab 600mg injection(600mg + 600mg/10ml)	1 Vial	Phesgo (Mfd. by M/s F. Hoffmann-La Roche Ltd., Switzerland)	1 vial	195000/1 Vial	Rupees One Lakh Ninety Five Thousand Only	L-1
167	Roche Products (India) Pvt. Ltd	2686	Polatuzumab Injection: Each vial/amp to contain Polatuzumab vedotin 30mg	1 Vial	Polivy 30mg (Mfd. by M/s F. Hoffmann-La Roche Ltd., Switzerland)	1 vial	142775/1 Vial	Rupees One Lakh Forty Two Thousand Seven Hundred Seventy Five Only	L-1
167	BDR Pharmaceuticals International Private Limited	2688	Pomalidomide Tab/Cap: Each Tab/Cap to contain Pomalidomide 1mg	1 Tab/Cap	BDPOMA 1MG	21 Cap	19.25/1 Cap	Rupees Nineteen Paise Twenty Five Only	L-1
167	NATCO Pharma Ltd	2689	Pomalidomide Tab/Cap: Each Tab/Cap to contain Pomalidomide 2mg	1 Tab/Cap	POMALID 2	21 Cap	55.00/1 Cap	Rupees Fifty Five Only	L-1
167	BDR Pharmaceuticals International Private Limited	2690	Pomalidomide Tab/Cap: Each Tab/Cap to contain Pomalidomide 4mg	1 Tab/Cap	BDPOMA 4MG	21 Cap	128.50/1 Cap	Rupees One Hundred Twenty Eight Paise Fifty Only	L-1
167	BDR Pharmaceuticals International Private Limited	2691	Rucaparib Tab/Cap: Each Tab/Cap to contain Rucaparib 200mg	1 Tab/Cap	BDPARIB 200	60 Tab	280/1 Tab	Rupees Two Hundred Eighty Only	L-1
167	BDR Pharmaceuticals International Private Limited	2692	Rucaparib Tab/Cap: Each Tab/Cap to contain Rucaparib 300mg	1 Tab/Cap	BDPARIB 300MG	60 Tab	326/1 Tab	Rupees Three Hundred Twenty Six Only	L-1
167	Zydus Lifesciences Limited	2693	Sirolimus Tab/Cap: Each Tab/Cap to contain Sirolimus 1 mg	1 Tab/Cap	SIROMUS	6 Tab	35.00/1 Tab	Rupees Thirty Five Only	L-1

ESIC

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	MSD PHARMACEUTICALS PRIVATE LIMITED	2696	Pneumococcal Inj. -0.5ml (23 Variant),0.5ml single dose	1 Vial/Amp/ PFS	Pneumovax 23 (Mfd. by Merck Sharp & Dohme, Netherlands)	0.5 ml single dose vial and PFS with needle	1134/1 PFS	Rupees One Thousand One Hundred Thirty Four Only	L-1
167	Naprod Life Sciences Pvt. Ltd.	1331b	Mitomycin Inj-Each Vial to contain: Mitomycin 10mg	1 Vial	Same as in Item	1 Vial	423.00/1 Vial	Rupees Four Hundred Twenty Three Only	L-1
167	Naprod Life Sciences Pvt. Ltd.	1407a	Epirubicin Inj-Each Inj to contain: Epirubicin Hydrochloride 10mg	1 Vial	4-Epeedo-10	1 Vial	185/1 Vial	Rupees One Hundred Eighty Five Only	L-1
167	Naprod Life Sciences Pvt. Ltd.	1407b	Epirubicin Inj-Each Inj to contain: Epirubicin Hydrochloride 50mg	1 Vial	Same as in Item	1 Vial	540/1 Vial	Rupees Five Hundred Forty Only	L-1
167	BDR Pharmaceuticals International Private Limited	1447a	Dasatinib Tab/Cap-Each Tab/Cap to contain: Dasatinib 20mg	1 Tab/Cap	DASH 20	60 Tab	9.27/1 Tab	Rupees Nine Paise Twenty Seven Only	L-1
167	Therdose Pharma Pvt Ltd	1447a	Dasatinib Tab/Cap-Each Tab/Cap to contain: Dasatinib 20mg.	1 Tab/Cap	Dasather 20	30 Tab	10.30/1 Tab	Rupees Ten Paise Thirty Only	L-2
167	BDR Pharmaceuticals International Private Limited	1447b	Dasatinib Tab/Cap-Each Tab/Cap to contain: Dasatinib 50mg	1 Tab/Cap	DASH 50	60 Tab	12.98/1 Tab	Rupees Twelve Paise Ninety Eight Only	L-1
167	Therdose Pharma Pvt Ltd	1447b	Dasatinib Tab/Cap- Each Tab/Cap to contain: Dasatinib 50mg	1 Tab/Cap	Dasather 50	15 Tab	17.00/1 Tab	Rupees Seventeen Only	L-2
167	Reliance Life Sciences Pvt. Ltd.	1449a	Rituximab Inj- Each vial to contain: Rituximab 100mg	1 Vial	RituxiRel 100ml	1 vial	1100/1 Vial	Rupees One Thousand One Hundred Only	L-1
167	Intas Pharmaceuticals Ltd.	1449a	Rituximab Inj- Each vial to contain: Rituximab 100mg	1 Vial	MABTAS 100	10ml vial	1630/1 Vial	Rupees One Thousand Six Hundred Thirty Only	L-2
167	Dr. Reddy's Laboratories Limited	1449a	Rituximab Inj- Each vial to contain: Rituximab 100mg	1 Vial	Reditux 100	1 vial	1646/1 Vial	Rupees One Thousand Six Hundred Forty Six Only	L-3

DG-ESIC Central Rate Contract No.167 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
167	Reliance Life Sciences Pvt. Ltd.	1449b	Rituximab Inj- Each vial to contain: Rituximab 500mg	1 Vial	RituxiRel 500ml	1 vial	4849/1 Vial	Rupees Four Thousand Eight Hundred Forty Nine Only	L-1
167	Dr. Reddy's Laboratories Limited	1449b	Rituximab Inj-Each vial to contain: Rituximab 500mg	1 Vial	Reditux 500	1 vial	5289/1 Vial	Rupees Five Thousand Two Hundred Eighty Nine Only	L-2
167	Intas Pharmaceuticals Ltd.	1449b	Rituximab Inj-Each vial to contain: Rituximab 500mg	1 Vial	MABTAS 500	50ml Vial	5345/1 Vial	Rupees Five Thousand Three Hundred Forty Five Only	L-3
167	CONCORD BIOTECH LIMITED	1474a	Everolimus Tab/Cap-Each-Tab/Cap to contain: Everolimus 0.25mg	1 Tab/Cap	Evercon 0.25	10 Tab	14.50/1 Tab	Rupees Fourteen Paise Fifty Only	L-1
167	Naprod Life Sciences Pvt. Ltd.	1474a	Everolimus Tab/Cap- Each Tab/Cap to contain: Everolimus 0.25mg	1 Tab/Cap	Same as in Item	10 Tab	15.00/1 Tab	Rupees Fifteen Only	L-2
167	CONCORD BIOTECH LIMITED	1474b	Everolimus Tab/Cap-Each Tab/Cap to contain: Everolimus 0.5mg	1 Tab/Cap	Evercon 0.5	10 Tab	32.40/1 Tab	Rupees Thirty Two Paise Forty Only	L-1
167	Naprod Life Sciences Pvt. Ltd.	1474b	Everolimus Tab/Cap - Each Tab/Cap to contain: Everolimus 0.5mg	1 Tab/Cap	Same as in Item	10 Tab	34/1 Tab	Rupees Thirty Four Only	L-2
167	BDR Pharmaceuticals International Private Limited	1476a	Deferasirox Tab/Cap-Each Tab/Cap to contain Deferasirox 100mg.	1 Tab/Cap	BDFEROX 100	10 Tab	1.74/1 Tab	Rupee One Paise Seventy Four Only	L-1
167	Intas Pharmaceuticals Ltd.	1650b	Filgrastim Inj-Each PFS/Vial to contain: Filgrastim 300 mcg	1 PFS/Vial	NEUKINE 300	1 Vial	89/1 PFS	Rupees Eighty Nine Only	L-1
167	Reliance Life Sciences Pvt. Ltd.	1650b	Filgrastim Inj-Each PFS/Vial to contain: Filgrastim 300 mcg	1 PFS/Vial	Religrast	1 PFS	104/1 PFS	Rupees One Hundred Four Only	L-2
167	Naprod Life Sciences Pvt. Ltd.	459a	Gemcitabine Inj-Each Vial to contain: Gemcitabine 200mg	1 Vial	Same as in Item	1 Vial	117/1 Vial	Rupees One Hundred Seventeen Only	L-1
167	Intas Pharmaceuticals Ltd.	459a	Gemcitabine Inj-Each Vial to contain: Gemcitabine 200mg	1 Vial	GEMIBINE 200	1 Vial	555/1 Vial	Rupees Five Hundred Fifty Five Only	L-2

END OF RATE CONTRACT

ESIC